The poor response to imatinib observed in CML patients with low OCT-1 activity is not attributable to lower uptake of imatinib into their CD34+ cells.

摘要: The functional activity of the organic cation transporter 1 (OCT-1) protein in chronic myeloid leukemia (CML) mononuclear cells (MNCs) is highly predictive molecular response imatinib treated patients. Here we investigate whether MNC OCT-1 (OA) provides a surrogate indicator effective targeting more immature CD34+ cells. While confirming our previous findings that high OA significantly associated with achievement major (MMR; P = .017), present studies found no relationship between and MMR. Furthermore, correlation was matched CML samples. These results suggest value may primarily reflect subsequent reduction mature Therefore kinase inhibition these cells, not be key determinant CML.